| Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer (NCT05522491) | Hebei Medical University Fourth Hospital | 2026-09-01 |
| SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma (NCT07744932) | Hebei Medical University Fourth Hospital | 2026-08-15 |
| SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma (NCT07668570) | Hebei Medical University Fourth Hospital | 2026-07-01 |
| Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC (NCT07697040) | Hebei Medical University Fourth Hospital | 2026-07-01 |
| A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction (NCT07607210) | Hebei Medical University Fourth Hospital | 2026-06-01 |
| A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer (NCT07585279) | Hebei Medical University Fourth Hospital | 2026-05-20 |
| Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. (NCT07528898) | Hebei Medical University Fourth Hospital | 2026-05-01 |
| Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC (NCT07448077) | Hebei Medical University Fourth Hospital | 2026-03-01 |
| ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy (NCT07410611) | Hebei Medical University Fourth Hospital | 2026-02-10 |
| Cardiac Safety Management and Immune Microenvironment Changes After Thoracic Radiotherapy: A Prospective Observational Study (NCT07669493) | Hebei Medical University Fourth Hospital | 2026-01-17 |
| Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) (NCT07289997) | Hebei Medical University Fourth Hospital | 2025-09-28 |
| Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics (NCT07131007) | Hebei Medical University Fourth Hospital | 2025-09-15 |
| Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer (NCT07492394) | Hebei Medical University Fourth Hospital | 2025-09-12 |
| This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy. (NCT06973525) | Hebei Medical University Fourth Hospital | 2025-09-01 |
| Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma. (NCT07266480) | Hebei Medical University Fourth Hospital | 2025-09-01 |
| Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study (NCT07004335) | Hebei Medical University Fourth Hospital | 2025-07-01 |
| Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) (NCT07057089) | Hebei Medical University Fourth Hospital | 2025-07-01 |
| Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study (NCT07019272) | Hebei Medical University Fourth Hospital | 2025-06-30 |
| Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection (NCT07434063) | Hebei Medical University Fourth Hospital | 2025-06-18 |
| Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer (NCT06949098) | Hebei Medical University Fourth Hospital | 2025-05-15 |
| Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR) (NCT06903871) | Hebei Medical University Fourth Hospital | 2025-04-01 |
| Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma (NCT07179900) | Hebei Medical University Fourth Hospital | 2025-03-01 |
| Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer. (NCT06851819) | Hebei Medical University Fourth Hospital | 2025-03-01 |
| Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC) (NCT06681285) | Hebei Medical University Fourth Hospital | 2024-11-01 |
| Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer (NCT05578053) | Hebei Medical University Fourth Hospital | 2024-09-13 |
| Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer (NCT06435260) | Hebei Medical University Fourth Hospital | 2024-08-01 |
| Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NCT06420908) | Hebei Medical University Fourth Hospital | 2024-05-30 |
| Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer (NCT07635342) | Hebei Medical University Fourth Hospital | 2024-04-30 |
| A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia (NCT06376435) | Hebei Medical University Fourth Hospital | 2024-04-20 |
| Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma (NCT06646588) | Hebei Medical University Fourth Hospital | 2024-04-01 |
| A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer (NCT06323265) | Hebei Medical University Fourth Hospital | 2024-03-26 |
| Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer (NCT06210971) | Hebei Medical University Fourth Hospital | 2024-02-01 |
| The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). (NCT06217185) | Hebei Medical University Fourth Hospital | 2024-01-02 |
| Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer (NCT06184698) | Hebei Medical University Fourth Hospital | 2024-01-01 |
| Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） (NCT06107673) | Hebei Medical University Fourth Hospital | 2023-09-30 |
| A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer (NCT06010667) | Hebei Medical University Fourth Hospital | 2023-09-01 |
| Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) (NCT06371482) | Hebei Medical University Fourth Hospital | 2023-06-01 |
| Subanesthetic Esketamine for Hemodynamic Stability and Recovery in Elderly Thoracic Surgery Patients (NCT07064408) | Hebei Medical University Fourth Hospital | 2023-06-01 |
| Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma (NCT06103890) | Hebei Medical University Fourth Hospital | 2023-05-22 |
| Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic (NCT06056115) | Hebei Medical University Fourth Hospital | 2023-05-01 |
| Minimally Residual of Esophageal Cancer 001 (NCT05952661) | Hebei Medical University Fourth Hospital | 2023-02-22 |
| Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors (NCT07490236) | Hebei Medical University Fourth Hospital | 2023-01-01 |
| Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer (NCT06009705) | Hebei Medical University Fourth Hospital | 2022-10-01 |
| Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer (NCT05512780) | Hebei Medical University Fourth Hospital | 2022-09-10 |
| Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer (NCT05241028) | Hebei Medical University Fourth Hospital | 2022-05-01 |
| Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer (NCT05525767) | Hebei Medical University Fourth Hospital | 2022-03-31 |
| Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer (NCT05086627) | Hebei Medical University Fourth Hospital | 2021-09-01 |
| Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer (NCT03728829) | Hebei Medical University Fourth Hospital | 2021-07-01 |
| Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor (NCT04282278) | Hebei Medical University Fourth Hospital | 2020-07-16 |
| A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC (NCT04286958) | Hebei Medical University Fourth Hospital | 2020-04-22 |
| Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer (NCT04290793) | Hebei Medical University Fourth Hospital | 2020-03-01 |
| Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer (NCT04159142) | Hebei Medical University Fourth Hospital | 2019-11-20 |
| Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer (NCT04138719) | Hebei Medical University Fourth Hospital | 2019-11-20 |
| A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer (NCT01907529) | Hebei Medical University Fourth Hospital | 2019-08-01 |
| Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC (NCT04067102) | Hebei Medical University Fourth Hospital | 2019-05-10 |
| Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study (NCT03919253) | Hebei Medical University Fourth Hospital | 2019-04-30 |
| Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma (NCT03964753) | Hebei Medical University Fourth Hospital | 2019-04-24 |
| A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma (NCT03857763) | Hebei Medical University Fourth Hospital | 2019-03-01 |
| A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations (NCT03634059) | Hebei Medical University Fourth Hospital | 2018-08-15 |
| Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR） (NCT06478355) | Hebei Medical University Fourth Hospital | 2018-01-01 |
| A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma (NCT03320629) | Hebei Medical University Fourth Hospital | 2017-11-01 |